Researchers at the Institute of Process Engineering (Chinese Academy of Sciences) introduced a ferritin aggregation cell engager (FACE) that links CAR‑T cells and leukemia cells via CD71, improving cell–cell engagement without reengineering CAR constructs. In preclinical leukemia PDX models the FACE‑augmented CAR‑T regimen matched efficacy with one‑fifth of the usual cell dose and reduced cytokine release syndrome risk, the team reported in Cell. FACE consists of an endogenous protein scaffold and clinically used polymer derivatives and can be applied as a culture supplement during CAR‑T manufacturing, enabling seamless integration into existing workflows. Corresponding author Wei Wei and collaborators emphasized FACE’s scalability and potential to address antigen escape by enhancing physical avidity between effector and target cells.